Haemonetics Corporation HAE
NYSE
| 09/26/2026 | 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | |
|---|---|---|---|---|---|
| Revenue | 357.76M | 339.38M | 346.35M | 338.97M | 327.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 357.76M | 339.38M | 346.35M | 338.97M | 327.32M |
| Cost of Revenue | 137.07M | 135.79M | 148.10M | 136.63M | 132.71M |
| Gross Profit | 220.69M | 203.59M | 198.26M | 202.34M | 194.60M |
| SG&A Expenses | 115.82M | 116.32M | 125.29M | 105.90M | 100.10M |
| Depreciation & Amortization | 10.40M | 10.20M | 10.49M | 10.93M | 11.18M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 280.32M | 278.52M | 298.29M | 267.75M | 258.52M |
| Operating Income | 77.44M | 60.86M | 48.07M | 71.22M | 68.80M |
| Income Before Tax | 62.86M | 47.57M | -28.40M | 59.98M | 51.29M |
| Income Tax Expenses | 16.55M | 14.56M | -8.25M | 15.24M | 12.60M |
| Earnings from Continuing Operations | 46.31M | 33.01M | -20.15M | 44.74M | 38.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.31M | 33.01M | -20.15M | 44.74M | 38.68M |
| EBIT | 77.44M | 60.86M | 48.07M | 71.22M | 68.80M |
| EBITDA | 105.20M | 87.97M | 69.29M | 98.60M | 97.05M |
| EPS Basic | 1.02 | 0.73 | -0.44 | 0.96 | 0.81 |
| Normalized Basic EPS | 0.90 | 0.70 | 0.51 | 0.85 | 0.81 |
| EPS Diluted | 1.00 | 0.72 | -0.44 | 0.95 | 0.81 |
| Normalized Diluted EPS | 0.88 | 0.70 | 0.51 | 0.85 | 0.81 |
| Average Basic Shares Outstanding | 45.50M | 45.36M | 46.22M | 46.79M | 47.59M |
| Average Diluted Shares Outstanding | 46.46M | 45.70M | 46.22M | 46.99M | 47.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |